

## lisinopril ICI

### Prescribing Notes

Consult data sheet before prescribing.

**Use:** All grades of essential hypertension and renovascular hypertension. Congestive heart failure adjunctive therapy.

**Presentation:** Tablets containing 2.5mg, 5mg, 10mg or 20mg lisinopril ('Zestril').

#### Dosage and administration:

**Hypertension** - initially 2.5mg daily, a 2.0mg dose seldom achieves a therapeutic response; adjust dose according to response. Maintenance usually 10-20mg once daily. Maximum is 40mg daily. Diuretic-treated patients - if possible stop diuretic 2-3 days before starting 'Zestril'. Resume diuretic later if desired.

**Congestive heart failure:** (adjunctive therapy) - initially 2.5mg daily in hospital under close medical supervision, increasing to 5-20mg once daily according to response.

**Impaired renal function:** May require a lower maintenance dose. 'Zestril' is dialysable.

**Elderly patients:** No change from standard recommendations.

**Contraindications:** Pregnancy - stop therapy if suspected. Hypersensitivity to 'Zestril'. Patients reacting with angioneurotic oedema to previous ACE inhibitor treatment.

**Precautions:** Assessment of renal function is recommended. Renal insufficiency, renovascular hypertension, surgery, anaesthesia, possibility of hypotension especially in ischaemic heart disease and cerebrovascular disease. Combination with antihypertensives may increase hypotensive effect. Sometimes increased blood urea and creatinine and/or cases of renal insufficiency if given with diuretics. Minimses thiazide-induced hyponatraemia and hyperuricaemia. Potassium supplements, potassium-sparing diuretics and potassium-containing salt substitutes not recommended. Indomethacin may reduce hypotensive effect. Possible reduced response in Afro-Caribbean patients. Use with caution in breastfeeding mothers. Do not use in aortic stenosis or outflow tract obstruction or cor pulmonale. Monitor lithium serum levels if lithium salts administered.

**Side effects:** Dizziness, headache, diarrhoea, fatigue, cough and nausea. Less frequently, rash and asthenia. Rarely, angioneurotic oedema and other hypersensitivity reactions, renal failure, symptomatic hypotension (especially if volume-depleted); severe hypotension (more likely if severe heart failure); palpitation; hyperkalaemia; increases in liver enzymes and serum bilirubin (usually reversible on discontinuation of 'Zestril'); and impotence.

**Product licence numbers and basic NHS cost:** 'Zestril' 2.5mg (29/02/81) 26 tablets, £7.84; 5mg (29/02/84) 26 tablets, £9.83; 10mg (29/02/85) 26 tablets, £12.13; 20mg (29/02/86) 26 tablets, £20.98.

'Zestril' is a trademark.

Further information is available from: ICI Pharmaceuticals (UK), Southbank, Alderley Park, Macclesfield, Cheshire SK10 4TF.



NOW  
INDICATED  
FOR  
FIRST-LINE  
ANTI-HYPERTENSIVE  
THERAPY



*Oh what a beautiful morning!*

Everyone has a certain zest for life. 'Zestril' lets your hypertensive patients enjoy theirs. 'Zestril' is an effective ACE inhibitor from ICI. 'Zestril' is taken once daily, so encouraging good patient compliance. A valuable aspect of 'Zestril' therapy is that it is well

tolerated, and suitable for a wide range of hypertensive patients. Your hypertensive patients will appreciate the convenient dosage and good tolerability of 'Zestril'. It's a therapy they'll find easy to live with - one which helps retain their zest for life.

*Morning, noon and night.*

## lisinopril ICI

Once daily for 24 hour BP control



**Antihypertensive therapy which helps retain that zest for life.**

Further information is available from: ICI Pharmaceuticals (UK), Southbank, Alderley Park, Macclesfield, Cheshire SK10 4TF.

1113242C NOV 87

# BMJ

1840-1990

Published weekly

## Associated Specialist Journals

Annals of the Rheumatic Diseases—monthly  
Archives of Disease in Childhood—monthly  
British Heart Journal—monthly  
Cardiovascular Research—monthly  
British Journal of Industrial Medicine—monthly  
British Journal of Ophthalmology—monthly  
Genitourinary Medicine—six issues a year  
Gut—monthly  
Journal of Clinical Pathology—monthly  
Journal of Epidemiology and Community Health—quarterly  
Journal of Medical Ethics—quarterly  
Journal of Medical Genetics—monthly  
Journal of Neurology, Neurosurgery and Psychiatry—monthly  
Thorax—monthly

## Professional and Scientific Publications

*A Registered Business Name of the BMA*

BDA News—19 issues a year  
BMA News Review—monthly  
British Dental Journal—24 issues a year  
British Journal of Anaesthesia—monthly  
Bulletin of Medical Ethics—10 issues a year  
Current Work in the History of Medicine—quarterly  
Eye—6 issues a year  
Health Visitor—monthly  
Medical History—quarterly  
Medical History Supplement—annual



For full details or a sample copy  
please contact

The Subscription Manager, *British Medical Journal* (or *Professional & Scientific Publications*),  
BMA House, Tavistock Square,  
London WC1H 9JR

## ABRIDGED PRODUCT INFORMATION

Refer to Data Sheet before prescribing.

### INDICATIONS

All grades of essential hypertension and renovascular hypertension. Congestive heart failure (adjunctive therapy).

### DOSAGE AND ADMINISTRATION

**Hypertension:** Initially, 5 mg once daily, reduce starting dose to 2.5 mg if over 65 years, on diuretics or renally impaired. Adjust dose according to response; maintenance usually 10-20 mg once daily. Maximum dose 40 mg daily.

Diuretic-treated patients – if possible stop diuretic two to three days before starting 'Innovace'. Resume diuretic later if required.

**Congestive heart failure (adjunctive therapy):** Initially, 2.5 mg daily in hospital under medical supervision, increasing to the usual maintenance dose of 10-20 mg once daily according to response.

**Impaired renal function:** May require a lower maintenance dose. 'Innovace' is dialysable.

### CONTRA-INDICATIONS

Pregnancy – stop therapy if suspected. Hypersensitivity to 'Innovace'. Patients reacting with angioneurotic oedema to previous ACE-inhibitor treatment.

### PRECAUTIONS

Assess renal function prior to therapy with 'Innovace' and during therapy where appropriate.

Renal insufficiency; possibility of hypotension especially in ischaemic heart disease or cerebrovascular disease or in volume-depleted patients; surgery/anaesthesia.

Combination with antihypertensives may increase hypotensive effect. In some patients with bilateral renal artery stenosis increased blood urea and creatinine has been seen, especially in patients treated with diuretics and/or those with renal insufficiency. Minimises thiazide-induced hypokalaemia and hyperuricaemia. Potassium supplements, potassium-sparing diuretics, and potassium-containing salt substitutes are not recommended.

Possible reduced response in Afro-Caribbean patients. Use with caution in breast-feeding mothers. Do not use in aortic stenosis, or outflow tract obstruction. Monitor serum levels of lithium, if lithium salts are given.

### SIDE EFFECTS

Side effects include: dizziness, headache. Others include fatigue, asthenia, nausea, diarrhoea, muscle cramps, rash, cough.

Less commonly, angioneurotic oedema; other hypersensitivity reactions; renal failure; symptomatic hypotension (especially if volume-depleted); severe hypotension (more likely if severe heart failure); hyperkalaemia, hyponatraemia; increases in liver enzymes and serum bilirubin (usually reversible on discontinuation of 'Innovace'); paraesthesiae; impotence.

### BASIC NHS COST

2.5 mg tablets, £10.00 for bottles of 50. 5 mg tablets, £7.86 for 28-day calendar pack; £14.03 for bottles of 50. 10 mg tablets, £11.03 for 28-day calendar pack; £19.69 for bottles of 50. 20 mg tablets, £13.10 for 28-day calendar pack; £23.40 for bottles of 50.

### Product licence numbers:

2.5 mg tablets, 0025/0220; 5 mg tablets, 0025/0194; 10 mg tablets, 0025/0195; 20 mg tablets, 0025/0196.

Issued February 1991.

® denotes registered trademark of Merck & Co., Inc., Rahway, NJ, USA

### References

1. Kjekshus, J., and Swedberg, K., *Amer. J. Cardiol.*, 1989, **63**, 26D.
2. Swedberg, K., and Kjekshus, J., *Drugs*, 1990, **39** (Suppl. 4), 49.
3. CONSENSUS Trial Study Group, *New Engl. J. Med.*, 1987, **316**, 1429.



Merck Sharp & Dohme Limited  
Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU